<DOC>
	<DOCNO>NCT00443612</DOCNO>
	<brief_summary>Primary : 1 . To compare change forearm vascular resistance follow 12-week regimen irbesartan/hydrochlorothiazide versus irbesartan 2 . To assess change serum proinflammatory cytokine , marker cardiovascular risk , oxidative stress circulate adhesion molecule include thiobarbiturate acid reactive substance ( TBARS ) , C-reactive protein ( CRP ) , interleukin 6 ( IL-6 ) , vascular cell adhesion molecule 1 ( VCAM-1 ) . Secondary : 1 . To compare reduction office blood pressure follow 12-week regimen irbesartan/hydrochlorothiazide versus irbesartan 2 . To compare response rate ( define office Systolic blood pressure ( SBP ) /diastolic blood pressure ( DBP ) reduce 10mmHg baseline ) , BP control rate ( define SBP &lt; 140 mmHg /or DBP &lt; 90 mmHg ) 3 . To ascertain safety tolerability irbesartan / hydrochlorothiazide versus irbesartan administer daily 4 . To determine whether angiotensin II type 1 ( AT-1 ) receptor gene polymorphism ( include A1166C gene 4 % minor allele frequency Chinese population single nucleotide polymorphism high frequency 10 % minor allele ) relate reduction BP</brief_summary>
	<brief_title>Irbesartan/Hydrochlorothiazide National Taiwan University Hospital Listing</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Patients mild moderate hypertension office diastolic BP ( DBP ) 90109 mmHg and/or systolic BP ( SBP ) 140179 mmHg enter treatment female : pregnant breast feeding office DBP ≧ 110 mmHg office SBP ≧ 180 mmHg history significant cardiovascular disease include : acute myocardial infarction within six month ischemic heart disease require medication , cerebrovascular disease history significant renal disease include : serum creatinine &gt; 3.0 mg/dl , creatinine clearance &lt; 30 ml/min . severe biliary cirrhosis cholestasis refractory hypokalemia , hypercalcemia history autoimmune disease , collagen vascular disease , multiple drug allergy , bronchospastic disease malignancy require current medication hepatic disease indicate follow : Serum Glutamic Oxaloacetic Transaminase ( SGOT ) Serum Glutamic Pyruvate Transaminase ( SGPT ) &gt; 3 x upper limit normal , serum bilirubin &gt; 2 x upper limit normal The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>